Meglitinides drug class for Type 2 diabetes treatment include repaglinide (Prandin) and nateglinide (Starlix) as oral diabetic medications. High fasting insulin levels and a reduction in insulin action may be present in person with Type 2 diabetes symptoms but so is absent or blunted first-phase insulin response to a meal. Most sulfonylureas (except Amaryl glimepiride) increase pancreatic beta-cell insulin secretion as well as plasma insulin concentration in people with Type 2 diabetes symptoms. But sulfonylureas oral diabetic medications fail to improve first-phase insulin release. Here comes meglitinides for Type 2 diabetes treatment. Starlix (nateglinide) and Prandin (repaglinide) as oral diabetic medications do increase first-phase insulin response, allowing to control sugar levels in blood after a meal. Both Starlix 60 mg pills and Prandin 1 mg pills are rapid-acting insulin secretagogues. When Prandin or Starlix meglitinides are taken 15 to 20 minutes before a meal, postprandial glucose excersions can be contained and minimized by this oral diabetic medications. This is important because high glucose level after a meal has been linked to cardiovascular diabetic complication.
Tag Archives: to control sugar level in blood
There is considerable interest in the dipeptidyl peptidase IV (DPP-IV) medications for type 2 diabetes treatment because, as a class, dipeptidyl peptidase IV drugs such as Januvia 25 mg pills (sitagliptin) appear to be well tolerated by people on type 2 diabetes treatment and can be used efficiently as monotherapy or as combination therapy together with Metformin (Glucophage, Fortamet, Glumetza drugs) oral diabetic medications. Beneficial effects of Januvia (sitagliptin) and dipeptidyl peptidase IV inhibitors as class on the pancreas beta-cell function raise the possibility that these sitagliptin agents of DPP-IV inhibitors may be able to modify the natural history of type 2 diabetes, given that Januvia used in proper type 2 diabetes treatment plan.